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Abstract
Background: In recent years, human microbiota, especially gut microbiota, have emerged as an important yet
complex trait influencing human metabolism, immunology, and diseases. Many studies are investigating the forces
underlying the observed variation, including the human genetic variants that shape human microbiota. Several
preliminary genome-wide association studies (GWAS) have been completed, but more are necessary to achieve a
fuller picture.
Results: Here, we announce the MiBioGen consortium initiative, which has assembled 18 population-level cohorts
and some 19,000 participants. Its aim is to generate new knowledge for the rapidly developing field of microbiota
research. Each cohort has surveyed the gut microbiome via 16S rRNA sequencing and genotyped their participants
with full-genome SNP arrays. We have standardized the analytical pipelines for both the microbiota phenotypes
and genotypes, and all the data have been processed using identical approaches. Our analysis of microbiome
composition shows that we can reduce the potential artifacts introduced by technical differences in generating
microbiota data. We are now in the process of benchmarking the association tests and performing meta-analyses
of genome-wide associations. All pipeline and summary statistics results will be shared using public data
repositories.
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Conclusion: We present the largest consortium to date devoted to microbiota-GWAS. We have adapted our
analytical pipelines to suit multi-cohort analyses and expect to gain insight into host-microbiota cross-talk at the
genome-wide level. And, as an open consortium, we invite more cohorts to join us (by contacting one of the
corresponding authors) and to follow the analytical pipeline we have developed.
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Background
Our understanding of the microbial communities popu-
lating the human body (human microbiota) has pro-
gressed tremendously in recent years, catalyzed by the
use of next-generation sequencing techniques that over-
come the limitations of anaerobic cultivation [1]. Much
effort has been devoted to understanding the taxonomic
and functional diversity of the microbiota and their
encoded collective gene pool, the microbiome, with most
research activity focusing on the microbes in our gastro-
intestinal tract [2, 3]. Much of the research has centered
on elucidating links between microbes and various dis-
eases [4], for instance, obesity, inflammatory bowel dis-
ease, and diabetes. This has including several studies
that went beyond association to demonstrate causal roles
of the gut microbiome in disease development.
More knowledge of the microbial ecosystem and the
role of different factors in its structure is an essential
path leading to more understanding of human biology
[5]. Cross-sectional studies carried out in several
population-based cohorts have identified the major en-
vironmental factors (nutrition, medication, and diet) in-
fluencing the composition and functional capacities of
the human microbiome [6, 7]. Yet these studies also
showed that a large proportion of microbial diversity
remained unexplained after considering the environmen-
tal influences, thereby raising questions on the role of
host genetics.
Given the complex interplay between the microbiome
and host physiology, a certain percentage of host genetics,
as well as genetic interactions with environmental factors,
is expected to shape the composition of the microbial
community [8]. Proof-of-principle genome-wide screens
(e.g., quantitative trait loci (QTL) studies) have been car-
ried out in model organisms like mouse [9], while the ma-
jority of published studies on humans have used a
candidate gene approach to cope with sample size limita-
tions. Recently, analyses of twin cohorts have demon-
strated a genetic contribution to variation in the relative
proportions of specific members of microbiota [10], for
example, investigations in 1126 twins identified associa-
tions to 28 loci, including genetic variants in LCT [11].
Bonder et al., Turpin et al., and Wang et al. then sim-
ultaneously reported GWAS results from three inde-
pendent cohorts, each revealing glimpses into the
genetic landscape underlying the gut microbiota struc-
ture [12–14]. Together, these GWAS have identified
some 100 genome-wide significant loci associated with
community structure, taxon abundance, and gut micro-
biome biodiversity. However, similar to initial GWAS ef-
forts in many other complex traits, there was little
overlap seen in the three sets of summary statistics
(Fig. 1). SLIT3 was the only gene to pass a standard
genome-wide significance threshold of 5 × 10−8 in the
TwinsUK and Bonder et al. studies [11, 12], but the two
reported single nucleotide polymorphisms (SNPs) within
this gene are not proxies of each other, nor do they cor-
relate to the same bacteria or pathway. Despite little
overlap in the associated genetic variants, which were
limited to the LCT locus, associations to various C-type
lectin genes were observed by both Bonder et al. and
Wang et al. [11, 12, 14]. These discordances emphasize
the need to increase the number of samples in the dis-
covery setting to improve statistical power and to reduce
the probability of false-positive associations.
Cross-multi-cohort analysis will also overcome limita-
tions imposed by population stratification as well as
technical artifacts, including the differences in model
choice [15].
We have therefore established the MiBioGen consor-
tium to study the influence of human genetics on gut
microbiota. This collaborative effort currently comprises
18 cohorts worldwide and new members will join us after
completing their data collection. We aim to develop a uni-
form pipeline to allow maximum harmonization across
the microbiome data and to use GWAS meta-analyses to
provide a fuller picture of human gene-microbiome asso-
ciations. Furthermore, since all the cohorts have been well
phenotyped, their data will aid future investigations into
other research questions.
MiBioGen initiative and cohort descriptions
Most of the 18 studies participating in the consortium are
prospective cohort studies in countries in Europe, Asia, and
North America (Table 1). Besides genetics and microbiome
data, the cohorts have also been deeply phenotyped, cover-
ing multiple individual outcomes (e.g., anthropometric,
metabolic, disease-related). These cohorts also incorporate
a wide age spectrum, including both children and adults.
The number of individuals per cohort study ranges from
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139 to 2482, with a total of 19,790 individuals (18,965 after
quality control (QC)). In terms of both sample size and
geographic distribution, the MiBioGen consortium is, to
our knowledge, the most comprehensive effort for investi-
gating host-genetics-versus-microbiome-associations on a
population scale.
As we have multiple phenotypes in addition to
microbiome and host genotypes available, we can as-
sess the putative effect of the gut microbiome on hu-
man health. Several of the cohorts were set up to
investigate certain phenotypes and/or diseases, for in-
stance, GEM (healthy relatives of patients with
Crohn’s disease) [13], or FoCus (a nutritional interven-
tion study) [14]. As a basis for epidemiological studies,
various metadata were collected by the different co-
horts including anthropometric measures, blood
chemistry, dietary pattern, intestinal permeability, and
lifestyle. These factors have been shown to influence
microbiota composition [6, 7, 14]. All these metadata
and phenotypes provide opportunities for assessing
the biological significance of gene-microbiome associ-
ations, and for gaining insights into gene-environment
interactions and the interaction between host geno-
type–microbiome–diseases.
Methods
To provide a platform for robust and reliable results
and also to simplify study participation in MiBioGen,
we have standardized all the procedures and protocols
that participating cohorts need to follow. The MiBio-
Gen data processing pipeline comprises four steps: (1)
microbiome data processing, (2) genotype data pro-
cessing, (3) genome-wide association analyses, and (4)
meta-analyses.
Fig. 1 Overview of genome-wide significant loci discovered in four recent GWAS studies [9–12]. For simplicity, only the regions harboring a coding gene
are shown, and for Wang et al. [14], the list was further refined to genes implicated in previous mouse QTL studies and to additional loci identified by an
improved method (shown in gray, Rühlemann et al. Gut microbes, 2017). So far, the only overlap found in the three studies is the SLIT3 locus, although
two studies reported two SNPs not in linkage disequilibrium. The LCT locus was not significant in the initial analysis using an additive model, but analyzing
functional SNPs in the recessive model identified a significant association for LCT in the Dutch cohort [15]
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Microbiome data processing
The microbiome data included in our consortium was
mainly generated using an Illumina sequencing platform
(MiSeq or HiSeq). The most frequently sequenced
hyper-variable region of the 16S rRNA gene was V4 (eight
cohorts, n = 8472), although five cohorts sequenced the
V3-V4 region (n = 5719), and another four sequenced the
V1-V2 region (n = 4774). We assessed the compatibility of
the datasets obtained from sequencing different regions by
comparing technical replicates of ten samples (three repli-
cates each) generated from different hyper-variable regions.
This analysis showed that the influence of technical differ-
ences in microbiome profiles is less than the
inter-individual differences (Additional file 1). Nevertheless,
including different hyper-variable regions requires compat-
ible methods of 16S rRNA gene-amplicon data processing,
and it is no longer feasible to use “open” (de novo) oper-
ational taxonomic units (OTU) picking protocols. Further
analysis of technical replicates using closed-reference OTU
picking showed that the clustering results also have large
technical artifacts (Additional file 1). In contrast, the
between-replicate similarity on genera- and higher
taxonomic levels showed reasonable concordance (Add-
itional file 1). As a result, we implemented the 16S data
processing pipeline, which comprised a naive Bayesian clas-
sifier from the Ribosomal Database Project [16], and the
most recent, full, SILVA database (release 128): we only an-
alyzed taxonomical results using genus- and higher taxo-
nomic levels.
As well as a standard taxonomy binning procedure, all
the additional steps have been standardized across the
consortium, including downsampling to 10,000 reads
with fixed seed to allow for replicability, procedures of
transformations, and corrections for covariates, and the
thresholds set for bacterial taxa to be included in the
analysis (any taxon should be present in more than 10%
of the cohort’s samples). This filtering effectively reduces
the total number of tests and also makes
cross-validation and meta-analysis feasible among all the
participating cohorts. 16S data processing is currently
being performed in all the cohorts and shows a high
level of congruence: the core-measurable microbiome
(CMM) [9], defined as the list of bacterial taxa present
in more than 10% of the samples in a cohort, is stable
Table 1 Information on the 18 cohorts participating in the MiBioGen consortium to date
Cohort name Population (ethnicity) 16S
domain
Genotyping platforms used Sample size
(after QC)
Description
BSPSPC Germany (Caucasian) V1-V2 Illumina 550K, Immunochip, Metabochip,
Affymetrix 6.0, Axiom
912 Representative of population
CARDIA USA (Caucasian and
African-American)
V3-V4 Illumina Exome, Affymetrix 6.0 282 Representative of population
NeuroIMAGE +
COMPULS
Netherlands (Caucasian) V1-V2 PsychChip (Broad Institute, Boston, USA) 153 Healthy group + ADHD group
COPSAC Denmark (Caucasian) V4 Illumina OmniExpressExome 424 Children (unselected)
FGFP Belgium (Caucasian) V4 Illumina OmniExpressExome 2482 Representative of population
FoCus Germany (Caucasian) V1-V2 Illumina Immunochip, Exome 1555 Representative of population +
obese sub-cohort
GEM Canada, USA, Israel
(Caucasian, Israeli)
V4 Illumina HumanCoreExome, Immunochip 1543 Healthy individuals
Generation R Netherlands (multi-ethnic) V3-V4 Illumina 610 k 2111 Representative of population
KSCS South Korea (Eastern
Asian)
V3-V4 Illumina HumanCore BeadChips 12v 833 Representative of population
LLD Netherlands (Caucasian) V4 Illumina Immunochip, Cytochip 1089 Representative of population
METSIM Finland (Caucasian) V4 Illumina OmniExpressExome 531 Representative of population
MIBS Netherlands (Caucasian) V4 Illumina OmniExpressExome 111 Healthy volunteers
PNP Israel (Israeli) V3-V4 Illumina Metabochip 1066 Healthy volunteers
Rotterdam Study Netherlands (Caucasian) V3-V4 Illumina 550k 1427 Representative of population
SHIP Germany (Caucasian) V1-V2 Affymetrix 6.0, Illumina OmniExpressExome,
Exomechip
1904 Representative of population
TwinsUK UK (Caucasian) V4 HumanHap300, Hap610Q, 1M-Duo,
1.2M-Duo
1793 Twins
NTR Netherlands (Caucasian) V4 Affymetrix 6.0 499 Twins
PopCol Sweden V1-V2 Illumina MiSeq 250 Representative of population
Total 18,965
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across the participating cohorts and shapes around 80%
of each cohort’s microbiome composition.
Genotype data processing
Individual genome-wide genotype data was gener-
ated by the different cohort studies using different
genotyping platforms and arrays (Table 1). In order
to utilize the genome-wide data and remove arti-
facts resulting from the different platforms, we im-
puted missing genotypes to extend the resolution
on a genome-wide level. We standardized the im-
putation procedure for each cohort, including the
pre-imputation quality control, reference imputation
panel, imputation server and software, as well as
the post-imputation filtering to include SNPs in the
analyses.
Quality control performed prior to imputation was
carried out by each cohort independently according to
our general recommendations. Imputation was per-
formed on a freely available Michigan server (https://
imputationserver.sph.umich.edu/index.html) that uses a
two-step approach: phasing with the Eagle v2.3 algo-
rithm, followed by imputation with Minimac [17]. For
our consortium, the data was imputed to the Haplotype
Reference Consortium (HRC 1.1) reference panels [17].
To allow imputed SNPs in the association studies, we in-
cluded minor allele frequency filtering (5%), posterior
imputation quality (0.4, applied per sample), and variant
imputation quality (0.5, applied per SNP). After imput-
ation, each study yielded around 39.1 million SNPs, with
4 to 6 million variants passing post-imputation QC.
Genome-wide association analysis
Previous microbiome GWAS have used different statistical
methods to test association of genetic variants with gut
microbiome taxa [9–12], and these might contribute to
some of the differences in observed associations. We are
therefore developing a uniform analytical pipeline to be im-
plemented by all the studies participating in our consor-
tium; it uses flexible statistical approaches to cope with the
non-normality and high dispersion inherent to microbiome
data [15]. Several layers of microbiome representations are
considered as traits in GWAS: general diversity metrics
(alpha- and beta-diversity), series of binomial traits of bac-
terial presence, and quantitative traits of bacterial relative
abundance. At the moment, we are using multiple cohorts
for benchmarking, to fine-tune our algorithm and to reduce
inter-cohort and technical differences.
Meta-analyses
Given the substantial increase in sample size (10-fold),
as well as our large number of 18 cohorts, we expect to
be able to identify individual bacteria and new genomic
loci that affect microbiome composition in general.
Based on the effect size (0.147 × SD, using a
genome-wide threshold of 5e−8) in some 1800 individ-
uals [14], this consortium can theoretically provide 80%
power to detect effects larger than 0.045 × SD. Our full
pipeline can be found and followed at https://github.-
com/alexa-kur/miQTL_cookbook. We will also publish
summary statistical results from each cohort, as well as
the full meta-study results, both on GitHub and as sup-
plementary files in our future publications.
Conclusions and future directions
The MiBioGen consortium’s large-scale meta-analysis of
18 cohorts drawn from different populations will permit
us to explore the genetic architecture of the gut micro-
biome. In addition to classic association studies, we will
adopt more sophisticated approaches to gain a better
understanding of the role of the gut microbiome as a
mediator between genetic predisposition and human
health/disease. For example, we will explore the associ-
ation of individual risk scores [18] to common diseases,
based on published GWAS results and individual micro-
biome composition.
We will also explore human gene-environment inter-
actions with respect to gut microbiome composition.
Such interactions have been observed for the LCT
non-functional variant and for dairy intake in relation to
the abundance of Bifidobacteria [10, 19]. Comprehensive
studies have explored the independent effects of envir-
onmental and genetic forces on the gut microbiome [6,
7, 12–14], and we will investigate a number of
gene-environment interactions of interest, including
gene-diet, using the combined genetic data and extensive
environmental metadata. Certain gene-environment in-
teractions can also be examined in those cohorts that
collected stool samples at multiple time points. We ap-
preciate that it will be difficult to determine causality,
but we will probably be able to identify a series of
environment-gene-microbiome triangles, for instance,
those involving age, gender, medication usage, or body
mass index. Our results will lead to hypotheses on the
links underlying microbiome-related physiological pro-
cesses. We would therefore encourage any cohorts with
an interest in analyzing host-microbiota associations in
their own data to join the MiBioGen consortium and to
contribute to more overall insights into the intricacies of
host genomes’ role in shaping the gut microbiota.
Finally, the additional phenotypes available in each co-
hort will provide a unique opportunity for quantifying
the contribution of the gut microbiome to different phe-
notypes. For example, GWAS analyses have already been
focused on metabolic traits and diseases in different co-
horts, and much more cross-checking can be carried out
using the EBI GWAS Catalog. The overlap in significant
loci will reveal intrinsic relationships between the
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microbiome, genetics, and diseases, thereby adding to
our knowledge of the molecular basis of these patholo-
gies. Recently developed strategies, such as linkage dis-
equilibrium score regression [20] and polygenic risk
scores [18], as well as downstream pathway enrichment
analyses, will help translate genetic associations into real
biological insights into the host-microbiome interaction.
Our consortium will thus not only contribute to funda-
mental knowledge on the gut microbiome but also lead
on to clinical and therapeutic efforts in treating diseases.
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